Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer

Exclusion Criteria

• •No prior therapy with capecitabine or oxaliplatin in any setting
• •No prior therapy with other platinum compounds·
• •No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to beginning protocol therapy.·
• •No prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil.·
• •No prior fluoropyrimidine therapy for metastatic disease is allowed. Prior adjuvant fluoropyrimidine therapy is allowed if completed \> 12 months from study entry.·
• •Maximum of one prior chemotherapy regimen for unresectable, locally recurrent or metastatic disease·
• •No symptomatic brain metastasis. ·
• •No evidence of serious concomitant systemic disorders incompatible with the study ·
• •No peripheral neuropathy ·
• •No major surgery within 28 days prior to beginning protocol therapy.·
• •Negative pregnancy test·
• •No female patients currently breastfeeding·
• •No malabsorption syndrome·
• •No evidence of serious concomitant systemic disorders incompatible with the study·
• •Patients must not be treated with any of the following while on protocol therapy or within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine, allopurinol.